​

Cellectar Biosciences (CLRB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

CLRB Stock Forecast

Cellectar Biosciences (CLRB) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 266.97% increase from the last price of $3.27.

- $3 $6 $9 $12 $15 High: $12 Avg: $12 Low: $12 Last Closed Price: $3.27

CLRB Stock Rating

Cellectar Biosciences stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

CLRB Price Target Upside V Benchmarks

TypeNameUpside
StockCellectar Biosciences266.97%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.27$3.27$3.27
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-21--3
Feb, 26-22--4
Jan, 26-22--4
Dec, 25-22--4
Nov, 25-22--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 28, 2024Jeff JonesOppenheimer$12.00$3.64229.67%266.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2025Roth CapitalBuyBuyhold
May 14, 2024OppenheimerOutperformOutperformhold
Mar 28, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-104.99$-36.52$-8.35---
Avg Forecast$-2.68$-1.61$-0.70$-0.98$-0.79$-0.56
High Forecast$-2.27$-1.47$-0.64$-0.62$-0.50$-0.56
Low Forecast$-3.08$-1.74$-0.74$-1.34$-1.42$-0.56
Surprise %3817.54%2168.32%1092.86%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$1.75M$15.00M$92.03M$153.02M$152.06M
High Forecast-$1.75M$15.00M$92.03M$153.02M$152.06M
Low Forecast-$1.75M$15.00M$92.03M$153.02M$152.06M
Surprise %------

Net Income Forecast

$-45M $-37M $-29M $-21M $-13M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.77M$-44.58M$-21.79M---
Avg Forecast$-32.71M$-19.64M$-8.43M$-11.98M$-11.73M$-6.81M
High Forecast$-27.73M$-18.02M$-7.79M$-7.58M$-6.11M$-6.81M
Low Forecast$-37.70M$-21.26M$-9.08M$-16.38M$-17.35M$-6.81M
Surprise %30.74%126.96%158.34%---

CLRB Forecast FAQ

Is Cellectar Biosciences stock a buy?

Cellectar Biosciences stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cellectar Biosciences is a favorable investment for most analysts.

What is Cellectar Biosciences's price target?

Cellectar Biosciences's price target, set by 8 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 266.97% change from the previous closing price of $3.27.

How does Cellectar Biosciences stock forecast compare to its benchmarks?

Cellectar Biosciences's stock forecast shows a 266.97% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cellectar Biosciences over the past three months?

  • March 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Cellectar Biosciences’s EPS forecast?

Cellectar Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.98, marking a -88.26% decrease from the reported $-8.35 in 2025. Estimates for the following years are $-0.79 in 2027, and $-0.56 in 2028.

What is Cellectar Biosciences’s revenue forecast?

Cellectar Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $92.03M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $153.02M, and $152.06M for 2028.

What is Cellectar Biosciences’s net income forecast?

Cellectar Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-11.977M, representing a -45.04% decrease from the reported $-21.791M in 2025. Projections indicate $-11.733M in 2027, and $-6.814M in 2028.